Two positive tests can answer one question well—and leave another unanswered. Consider this illustrative case: a 34-year-old woman with weeks of intermittent ptosis now coughs with liquids and develops nasal speech after prolonged conversation. Her strength is full at rest, but sustained upgaze and repeated jaw closure expose weakness. A positive AChR-binding antibody and a reported 16% decrement on low-frequency RNS, read with this phenotype, strongly support AChR-antibody-positive autoimmune MG if the decrement is reproducible and technically valid. Neither result measures current respiratory reserve or makes technical review unnecessary.
The clinical stakes are twofold: localize the fluctuating deficit correctly while separately assessing new bulbar symptoms.
Let the phenotype set the prior
The useful history is task-linked change, not a general report of tiredness: eyelid position worsens with sustained upgaze, chewing becomes less effective near the end of a meal, and speech changes with prolonged use. The timeline is short and fluctuating; there is no reported sensory loss, and reflexes are preserved. Normal limb power during a brief resting examination does not erase that pattern.
This constellation localizes toward impaired neuromuscular transmission. It raises MG substantially, but the examination still matters: fixed deficits, prominent sensory or long-tract signs, or a steadily progressive course would prompt a broader search. The absence of those findings is supportive context, not a standalone diagnostic rule.
Read the decrement—and inspect the study
The CMAP falls from 5.0 to 4.2 mV: a decrease of 0.8 mV, or 16% of the initial response. A reproducible decrement of at least 10% between the first and fourth or fifth response during low-frequency stimulation is a traditional electrodiagnostic abnormality used to support MG. It is not a universal, stand-alone diagnostic criterion: interpretation depends on the protocol, the muscle recorded, and whether the change is reproducible.
An international European consensus group in 2025 proposed minimum electrodiagnostic evidence for a neuromuscular-transmission disorder as two abnormal RNS studies, one abnormal RNS study plus one abnormal single-fiber EMG (SFEMG), or two abnormal SFEMG studies. These are proposed electrodiagnostic criteria, not universal clinical diagnostic criteria for MG; clinical findings and serology remain part of the overall formulation. The vignette reports one decrement value but does not state how many nerve-muscle pairs were tested or whether other results were abnormal.
Ask whether the nerve supplying a clinically relevant muscle was tested and whether the recording was technically sound. Movement, unstable electrode placement, inadequate limb immobilization, or inappropriate temperature can undermine interpretation. A 16% decrement that is reproducible in a well-performed study carries more weight than a single unexplained drop in a trace.
Even a valid decrement is not unique to MG. Low-frequency decrement can occur in other neuromuscular-junction disorders, including Lambert-Eaton myasthenic syndrome (LEMS). In this patient, the antibody result and clinical pattern help determine what the physiology means.
A positive AChR antibody is strong evidence—not a shortcut
A positive AChR-binding antibody fits the fatigable ocular-bulbar syndrome and abnormal RNS, making AChR-antibody-positive autoimmune MG the leading formulation. The result adds important etiologic evidence; it is not simply a second way of measuring the same thing as the CMAP decrement.
Still, antibody results must be read against the phenotype and the assay’s reference range. A 2025 real-world retrospective study of radioimmunoprecipitation assay (RIPA) results found that some AChR-IgG-positive patients were ultimately considered not to have MG, particularly when titers were low and the clinical picture made MG unlikely. That caution is most useful in an atypical case—not a reason to discount converging evidence here. The reported titer and assay are not provided, so do not infer how strongly positive the result was from the word positive alone.
| Finding | What it supports | What it does not establish |
|---|---|---|
| Task-linked ptosis and chewing or speech weakness | A fluctuating neuromuscular pattern | A specific antibody or diagnosis by itself |
| Reported 16% low-frequency RNS decrement, if reproducible and technically valid | Abnormal neuromuscular transmission | MG specifically, or clinical severity |
| Positive AChR-binding antibody in this phenotype | AChR-antibody-positive autoimmune MG | Current respiratory reserve or airway safety |
Use discordance to choose the next test
If RNS is normal but clinical suspicion remains high, do not rule out MG. RNS sensitivity varies with the muscles tested and the distribution of weakness. The AAEM practice parameter recommends SFEMG of at least one symptomatic muscle when RNS is normal and suspicion remains high; if that study is normal despite strong suspicion, a second muscle may be considered.
If the antibody is positive but the phenotype is a poor fit, pause before assigning a lifelong diagnosis. Recheck the assay and titer, review the examination and timeline, and ask whether another explanation better accounts for the symptoms. Conversely, a negative AChR result would not negate a convincing clinical syndrome; it would change which confirmatory studies and antibody tests are useful.
Keep diagnostic certainty separate from urgency
The clinical pattern and positive antibody strongly support MG; a reproducible, technically valid RNS decrement adds electrophysiologic support. That convergence does not settle the separate question of how safely she swallows or breathes. These new bulbar symptoms warrant prompt assessment of swallowing safety, cough effectiveness, secretion handling, and respiratory function, with reassessment if function changes. Severe or worsening swallowing or breathing difficulty, a weak or ineffective cough, or inability to manage secretions warrants emergency evaluation.
A normal oxygen saturation does not rule out evolving respiratory muscle weakness and cannot substitute for clinical assessment and appropriate respiratory-function measurements. Acute risk follows the patient’s function and trajectory—not the size of the RNS decrement or the antibody result. Keep the diagnostic and safety decisions parallel.
Practical takeaways
- Calculate the decrement, then check that it is reproducible and technically interpretable.
- Treat the 10% threshold as a traditional RNS abnormality, not a universal stand-alone diagnostic rule; proposed electrodiagnostic criteria may require more than one abnormal study.
- Treat a positive AChR antibody as powerful evidence when the clinical phenotype fits; be more cautious with low-positive RIPA results in atypical presentations.
- A normal RNS does not exclude MG; if suspicion remains high, consider targeted SFEMG.
- Assess bulbar and respiratory function—not antibody status or decrement size—to judge immediate clinical risk.
